Viktor Grunwald: Real-world cabozantinib after ICI

Viktor Grunwald, Professor of Interdisciplinary Genitourinary (GU) Oncology at the University Hospital Essen, shared a post on X, about paper published in Clinical Genitourinary Cancer:

Final Analysis of a Noninterventional Study on Cabozantinib in Patients With Advanced Renal Cell Carcinoma After Prior Checkpoint Inhibitor Therapy of the German Interdisciplinary Working Group on Renal Tumors (IAG-N).

Authors: Grünwald Viktor, Bögemann Martin, Rafiyan Mohammad-Reza, Niegisch Günter, Schnabel Marco, Flörcken Anne, Maasberg Michael, Maintz Christoph, Zahn Mark-Oliver, Wortmann Anke, Hinkel Andreas, Casper Jochen, Darr C, Hilser Thomas, Schulze M, Sookthai Disorn, Ivanyi Philipp.

”Real-world cabozantinib after ICI:

• Similar efficacy (shorter OS) compared to METEOR. 
• 62% had lower starting doses (<60mg).
• Similar outcome in low vs. 60 mg starting dose.
• Less toxicity with lower dose.
• Let’s re-think cabozantinib dosing.”

Source: Viktor Grunwald/X